EGFR and non-small cell lung carcinoma: To test the efficacy of combining EGFR‐specific TKIs and 2XmAbs (cetuximab and trastuzumab) in such genetically more heterogeneous model systems, we made use of two PDX models of NSCLC, both from the Jackson Laboratory: TM00199, expressing L858R‐EGFR, and TM00193, expressing E746_A750 del‐EGFR.